Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib

Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Tatsuro, Noguchi, Kazuhiro, Hayashi, Shizuka, Irie, Sadaharu, Hayase, Risa, Shioya, Haruna, Kaneko, Youhei, Horio, Kensuke, Taguchi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778875/
https://www.ncbi.nlm.nih.gov/pubmed/29435021
http://dx.doi.org/10.3892/ol.2017.7720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778875/
https://www.ncbi.nlm.nih.gov/pubmed/29435021
http://dx.doi.org/10.3892/ol.2017.7720

Ejemplares similares